Biosimilars to treat retinal diseases: Successful outcomes, patient satisfaction
January 23rd 2024Two retina specialists participated in an Ophthalmology Times case-based roundtable discussion and shared their experiences using the anti-VEGF biosimilars, ranibizumab-eqrn and ranibizumab-nuna to manage retinal diseases.
Read More
Pupillometry as a potential biomarker for major depressive disorder
January 17th 2024A collaborative study between the Max Planck Institute of Psychiatry and the University of California, Irvine, explores the potential of pupillometry as a clinical test for identifying a specific subgroup of patients with major depressive disorder (MDD) characterized by anticipatory hypo-arousal related to anhedonia.
Read More
Acetylcholinesterase inhibitors associated with lower risk of AMD in Alzheimer’s Disease patients
January 12th 2024Because acetylcholinesterase inhibitors have anti-inflammatory effects, authors of the study wanted to determine if these drugs reduce the risk of AMD in patients with Alzheimer’s disease.
Read More